These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 9010987)

  • 1. Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin-induced emesis.
    Perez EA; Navari RM; Kaplan HG; Gralla RJ; Grunberg SM; Palmer RH; Fitts D
    Support Care Cancer; 1997 Jan; 5(1):31-7. PubMed ID: 9010987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of granisetron, a selective 5-hydroxytryptamine-3 receptor antagonist, in the prevention of nausea and vomiting induced by high-dose cisplatin.
    Navari RM; Kaplan HG; Gralla RJ; Grunberg SM; Palmer R; Fitts D
    J Clin Oncol; 1994 Oct; 12(10):2204-10. PubMed ID: 7931490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of intravenous granisetron to control nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.
    Ritter HL; Gralla RJ; Hall SW; Wada JK; Friedman C; Hand L; Fitts D
    Cancer Invest; 1998; 16(2):87-93. PubMed ID: 9512674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind, randomised comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy.
    Audhuy B; Cappelaere P; Martin M; Cervantes A; Fabbro M; Rivière A; Khayat D; Bleiberg H; Faraldi M; Claverie N; Aranda E; Auclerc G; Audhuy B; Benhammouda A; Bleiberg H; Cals L; Cappelaere P; Cattan A; Cervantes A; Chevallier B; Conroy T; Cupissol D; De Grève J; Diaz-Rubio E; Seitz JF
    Eur J Cancer; 1996 May; 32A(5):807-13. PubMed ID: 9081358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group.
    Navari R; Gandara D; Hesketh P; Hall S; Mailliard J; Ritter H; Friedman C; Fitts D
    J Clin Oncol; 1995 May; 13(5):1242-8. PubMed ID: 7738628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Granisetron plus methylprednisolone for the control of high-dose cisplatin-induced emesis.
    Kleisbauer JP; García-Girón C; Antimi M; Azevedo MC; Balmes H; Massuti-Sureda B; Contu A; Luque A; Pellier P
    Anticancer Drugs; 1998 Jun; 9(5):387-92. PubMed ID: 9660534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study.
    Perez EA; Hesketh P; Sandbach J; Reeves J; Chawla S; Markman M; Hainsworth J; Bushnell W; Friedman C
    J Clin Oncol; 1998 Feb; 16(2):754-60. PubMed ID: 9469367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of ramosetron and granisetron for the prevention of acute and delayed emesis in Cisplatin-based chemotherapy: a randomized controlled trial.
    Cheirsilpa A; Sinthusake T; Songsakkaesorn A; Visawaprasit S; Chulaka K; Changkuingdee N
    Jpn J Clin Oncol; 2005 Dec; 35(12):695-9. PubMed ID: 16319109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy of three 5-HT3 antagonists (granisetron, ondansetron, and tropisetron) plus dexamethasone for the prevention of cisplatin-induced acute emesis: a randomized crossover study.
    Chua DT; Sham JS; Kwong DL; Kwok CC; Yue A; Foo YC; Chan R
    Am J Clin Oncol; 2000 Apr; 23(2):185-91. PubMed ID: 10776982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy.
    Chevallier B; Cappelaere P; Splinter T; Fabbro M; Wendling JL; Cals L; Catimel G; Giovannini M; Khayat D; Bastit P; Claverie N
    Support Care Cancer; 1997 Jan; 5(1):22-30. PubMed ID: 9010986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of oral granisetron versus oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapy.
    Burris H; Hesketh P; Cohn J; Moriconi W; Ryan T; Friedman C; Fitts D
    Cancer J Sci Am; 1996; 2(2):85-90. PubMed ID: 9166505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Control of high-dose-cisplatin-induced emesis with an all-oral three-drug antiemetic regimen.
    Hesketh PJ; Roman A; Hesketh AM; Perez EA; Edelman M; Gandara DR
    Support Care Cancer; 2000 Jan; 8(1):46-8. PubMed ID: 10650897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy.
    Ettinger DS; Eisenberg PD; Fitts D; Friedman C; Wilson-Lynch K; Yocom K
    Cancer; 1996 Jul; 78(1):144-51. PubMed ID: 8646710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin-based chemotherapy. A prospective randomized trial.
    Gebbia V; Testa A; Valenza R; Cannata G; Tirrito ML; Gebbia N
    Cancer; 1995 Nov; 76(10):1821-8. PubMed ID: 8625054
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. The Ondansetron and Granisetron Emesis Study Group.
    Ruff P; Paska W; Goedhals L; Pouillart P; Rivière A; Vorobiof D; Bloch B; Jones A; Martin C; Brunet R
    Oncology; 1994; 51(1):113-8. PubMed ID: 8265095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized trial of two doses of granisetron in the treatment of chemotherapy-induced emesis. Dutch results within a multinational study.
    Bots MW; Dijkstra HJ; Blijham GH; van der Wall E; Fehmers MC; Keizer HJ; Nortier JW; Siegenbeek van Heukelom L; Slee PH; Veenhof CH
    Neth J Med; 1992 Jun; 40(5-6):221-6. PubMed ID: 1331830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of granisetron as a single agent with conventional combination antiemetic therapies in the treatment of cytostatic-induced emesis. The Granisetron Study Group.
    Marty M
    Eur J Cancer; 1992; 28A Suppl 1():S12-6. PubMed ID: 1320913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial.
    Mantovani G; Macciò A; Bianchi A; Curreli L; Ghiani M; Proto E; Santona MC
    Cancer; 1996 Mar; 77(5):941-8. PubMed ID: 8608488
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. The Granisetron Study Group.
    Heron JF; Goedhals L; Jordaan JP; Cunningham J; Cedar E
    Ann Oncol; 1994 Sep; 5(7):579-4. PubMed ID: 7993831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved control of high-dose-cisplatin-induced acute emesis with the addition of prochlorperazine to granisetron/dexamethasone.
    Hesketh PJ; Gandara DR; Hesketh AM; Edelman M; Webber LM; McManus M; Hainsworth JD
    Cancer J Sci Am; 1997; 3(3):180-3. PubMed ID: 9161784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.